Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease
In the Clarity AD Asian region cohort, the overall efficacy, biomarker changes and safety profile of lecanemab were consistent with the overall population, with a favorable risk-benefit profile and manageable risks. ARIA events and infusion-related reactions occurred less commonly with lecanemab in the Asian region subgroup than the overall population.
Authors
- Michio Kanekiyo
- Kentaro Torii
- Masaki Nakagawa (ORCID: https://orcid.org/0000-0001-7872-156X)
- Tomoo Ogawa
- Christopher Chen (ORCID: https://orcid.org/0000-0002-1047-9225)
- Shobha Dhadda (ORCID: https://orcid.org/0000-0002-7290-7168)
- Amitabh Dash (ORCID: https://orcid.org/0000-0002-9351-4021)
- Takeshi Iwatsubo (ORCID: https://orcid.org/0000-0003-1160-8129)
- Juneyoung Lee (ORCID: https://orcid.org/0000-0001-8073-9304)
- Jae Hong Lee (ORCID: https://orcid.org/0000-0002-9259-1391)
- Steve Hersch
- Michael C. Irizarry (ORCID: https://orcid.org/0000-0002-0246-2511)
- Sadao Katayama
Institutions
- Ulsan College (KR)
- Seoul National University (KR)
- National University of Singapore (SG)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- National Center of Neurology and Psychiatry (JP)
- Kurashiki Medical Center (JP)
- Kulicke & Soffa (Singapore) (SG)
- Eisai (United States) (US)
- Eisai (Japan) (JP)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1016/j.tjpad.2025.100160
- Citations
- 28
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 32.60
Funders
- Biogen
- Eisai